​

Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

REGN Stock Forecast

Regeneron Pharmaceuticals (REGN) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $836.00, with a high of $995.00 and a low of $641.00. This represents a 38.95% increase from the last price of $601.65.

$600 $720 $840 $960 $1 $1 High: $995 Avg: $836 Low: $641 Last Closed Price: $601.65

REGN Stock Rating

Regeneron Pharmaceuticals stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (66.67%), 16 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 16 32 0 Strong Sell Sell Hold Buy Strong Buy

REGN Price Target Upside V Benchmarks

TypeNameUpside
StockRegeneron Pharmaceuticals38.95%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts81556
Avg Price Target$783.88$826.27$799.43
Last Closing Price$601.65$601.65$601.65
Upside/Downside30.29%37.33%32.87%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 265168--29
May, 264187--29
Apr, 263187--28
Mar, 262178--27
Feb, 262178--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 19, 2026John NewmanCanaccord Genuity$875.00$629.6838.96%45.43%
May 18, 2026Alexandria HammondWolfe Research$860.00$629.3636.65%42.94%
May 18, 2026Evercore ISI$825.00$619.8433.10%37.12%
May 18, 2026RBC Capital$707.00$619.6214.10%17.51%
May 18, 2026Truist Financial$778.00$619.9525.49%29.31%
May 18, 2026BMO Capital$730.00$698.254.55%21.33%
May 18, 2026Piper Sandler$855.00$698.2522.45%42.11%
May 18, 2026Market PerformLeerink Partners$641.00$698.25-8.20%6.54%
May 01, 2026Yatin SunejaGuggenheim$995.00$707.0640.72%65.38%
Apr 30, 2026Terence FlynnMorgan Stanley$788.00$703.1812.06%30.97%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 18, 2026Wolfe ResearchOutperformOutperformhold
May 18, 2026CitigroupBuyNeutraldowngrade
May 18, 2026Bank of America SecuritiesBuyBuyhold
May 01, 2026GuggenheimBuyBuyhold
Apr 22, 2026Raymond JamesOutperformOutperformhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Mar 06, 2026BarclaysOverweightOverweightinitialise
Mar 02, 2026RBC CapitalSector PerformSector Performhold
Feb 24, 2026JefferiesHoldHoldhold
Feb 09, 2026GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$30 $40 $50 $60 $70 $80 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$76.40$40.51$37.05$40.90$43.07---
Avg Forecast$71.52$42.60$42.62$45.02$44.51$48.41$56.23$61.14
High Forecast$74.49$45.65$43.60$47.01$52.39$60.93$71.36$66.97
Low Forecast$67.49$40.10$39.84$43.54$34.72$38.38$43.10$56.27
Surprise %6.82%-4.91%-13.07%-9.15%-3.24%---

Revenue Forecast

$11B $13B $15B $16B $18B $20B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.07B$12.17B$13.12B$14.20B$14.34B---
Avg Forecast$15.70B$11.86B$12.94B$14.18B$14.63B$15.52B$17.22B$18.20B
High Forecast$16.20B$12.52B$13.07B$14.49B$15.28B$15.58B$17.22B$19.53B
Low Forecast$15.02B$11.33B$12.65B$14.04B$13.90B$15.46B$17.21B$17.08B
Surprise %2.39%2.62%1.37%0.15%-1.95%---

Net Income Forecast

$3B $4B $5B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.08B$4.34B$3.95B$4.41B$4.50B---
Avg Forecast$7.29B$4.49B$3.95B$5.15B$4.36B$4.65B$5.30B$6.95B
High Forecast$8.75B$5.39B$4.74B$5.34B$5.96B$6.93B$8.11B$7.61B
Low Forecast$5.83B$3.59B$3.16B$4.95B$3.95B$4.36B$4.90B$6.40B
Surprise %10.75%-3.36%--14.28%3.36%---

REGN Forecast FAQ

Is Regeneron Pharmaceuticals stock a buy?

Regeneron Pharmaceuticals stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Regeneron Pharmaceuticals is a favorable investment for most analysts.

What is Regeneron Pharmaceuticals's price target?

Regeneron Pharmaceuticals's price target, set by 48 Wall Street analysts, averages $836 over the next 12 months. The price target range spans from $641 at the low end to $995 at the high end, suggesting a potential 38.95% change from the previous closing price of $601.65.

How does Regeneron Pharmaceuticals stock forecast compare to its benchmarks?

Regeneron Pharmaceuticals's stock forecast shows a 38.95% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Regeneron Pharmaceuticals over the past three months?

  • June 2026: 17.24% Strong Buy, 55.17% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 13.79% Strong Buy, 62.07% Buy, 24.14% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 10.71% Strong Buy, 64.29% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Regeneron Pharmaceuticals’s EPS forecast?

Regeneron Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $48.41, marking a 12.40% increase from the reported $43.07 in 2025. Estimates for the following years are $56.23 in 2027, and $61.14 in 2028.

What is Regeneron Pharmaceuticals’s revenue forecast?

Regeneron Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $15.52B, reflecting a 8.21% increase from the reported $14.34B in 2025. The forecast for 2027 is $17.22B, and $18.2B for 2028.

What is Regeneron Pharmaceuticals’s net income forecast?

Regeneron Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $4.65B, representing an 3.12% increase from the reported $4.5B in 2025. Projections indicate $5.3B in 2027, and $6.95B in 2028.